Hyaluronate [Viscoseal] injection after knee surgery; an evaluation
| ISRCTN | ISRCTN10972486 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10972486 |
| IRAS number | 272362 |
| Secondary identifying numbers | CPMS 43835, IRAS 272362 |
- Submission date
- 10/02/2020
- Registration date
- 05/03/2020
- Last edited
- 22/11/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Ongoing
- Condition category
- Surgery
Plain English summary of protocol
Background and study aims
Arthroscopic, or keyhole, surgery on the meniscus in the knee joint has benefits over open surgery. Nonetheless, there is scope to further improve outcomes for patients by reducing pain and discomfort and promoting enhanced recovery of knee joint functionality. The medical device Viscoseal contains hyaluronan and is designed to replenish levels of this compound in the knee joint following arthroscopic repair of the meniscus. Natrually, synovial fluid in the knee joint contains hyaluronan, but a lot of it is washed away when surgeons flush the knee joint during surgery to remove loose pieces of meniscus, cartilage, or bone. Previous studies, both in laboratory studies and patient trials, have demonstrated that Viscoseal can promote re-establishment of biological structure in the knee joint to allow it to return to a normal physiological state and protect cartilage.
Who can participate?
Patients aged 18 – 59 years due to undergo meniscal surgery of the knee for meniscal tear grade III (including repair, partial meniscectomy or complete meniscectomy).
What does the study involve?
This present prospective, randomised, controlled trial aims to build on this evidence by comparing standard care versus the injection of Viscoseal (26 vs 26 patients) at the end of arthroscopic meniscus repair surgery. The degree of pain, leg swelling and knee functionality experienced by patients after surgery will be measured using validated patient surveys focused on the meniscus. In addition, a detailed picture of what happens to the meniscus after surgery +/- administration of Viscoseal will be obtained through MRI radiologic imaging. The main objective is to determine if Viscoseal can achieve a minimal clinically important difference in pain relief after meniscal repair surgery when compared to standard care.
What are the possible benefits and risks of participating?
Benefits: For participants in the control group there is no direct benefit for taking part in this study. You will be cared for in exactly the same manner as you normally would, bar the introduction of a few questionnaires and a potential extra MRI scan. However, by taking part you will contribute to comparison of the effectiveness of adding hyaluronate to a meniscus operation, to optimise management of meniscus surgery in the future. For participants in the Viscoseal® intervention group there may be benefits in terms of reduced pain and swelling after the procedure. However, this has not yet been proven and established beyond doubt, and this study is aimed to assess this further.
Risks: There is no significant personal safety risk anticipated regarding taking part in this study. Like with any invasive procedure, the meniscus surgery carries (post-operative) risks such as bleeding, blood clots and infection. However, the arhroscopic surgery itself is not classed as being part of this HIKE study; the injection of Viscoseal® at the end of the procedure is. Fifty percent of patients do not receive this and therefore for them there is no additional risk over and above that related to standard care.
Where is the study run from?
Cumbria Partnership NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
January 2020 to July 2025
Who is funding the study?
TRB Chemedica (UK) Ltd.
Who is the main contact?
Dr Leon Jonker
leon.jonker@nihr.ac.uk
Contact information
Scientific
North Cumbria Integrated Care NHS Foundation Trust
R&D Dept, Carleton Clinic
Carlisle
CA1 3SX
United Kingdom
| Phone | +44 (0)1228 608926 |
|---|---|
| leon.jonker@nihr.ac.uk |
Study information
| Study design | Interventional randomized controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A single-centre, randomised, placebo-controlled single-blinded trial assessing patient and clinical outcomes of Viscoseal injection after meniscal surgery |
| Study acronym | HIKE |
| Study objectives | To determine the level of index leg related pain experienced at day 7 post-operation and to compare the average pain scores of patients in the control and Viscoseal arm respectively, through administration of 100 mm visual descriptor scale (VDS) for pain at rest. |
| Ethics approval(s) | Approved 22/01/2020, NHS HRA Wales REC 7 (c/o Public Health Wales, Building 1, Jobswell Road, St David’s Park, SA31 3HB, UK; +44 (0)1267 611 164; sue.byng@wales.nhs.uk), ref: 19/EM/0363 |
| Health condition(s) or problem(s) studied | Elective orthopaedic surgery |
| Intervention | - Standard care (control) arm All patients receive general anesthesia and a pneumatic tourniquet is used. Patients are already randomised prior to surgery to avoid delays with surgery and allow a vial of Viscoseal to be ready for the relevant patients. Joint irrigation is performed with the assistance of a manual arthroscopic pump using 0.9% NaCl solution at room temperature. Then, the remaining fluids are drained from the knee. At the end of the surgery, the knee is dressed while the tourniquet is still inflated. All surgeries are intended to be performed in a day-surgery facility with the patient being discharged the same day. Postoperatively, partial weight-bearing with crutches is allowed. Crutches are recommended for the first 48 hours, primarily for patient safety by minimising the risk of a fall. - Viscoseal (intervention) arm Apart from the difference in terms of Viscoseal administration to the intervention group, the surgical protocol for the Viscoseal arm is identical to that of the standard care group. At the end of the surgery, again all the remaining fluids are drained from the knee, but this is followed by injection of 10 mL of Viscoseal preparation. Used Viscoseal product and syringes will be disposed of in line with local guidelines on disposal of clinical waste. Timeline and overview of different study visits Visit 1# Pre-surgery (<0 weeks) Written Informed Consent, Collection of baseline information (age, weight etc), Record use of any pain medication, Limb girth measurement, Validated patient-reported outcome measures (Lysholm scale; WOMET tool; Visual display scale for knee pain) Visit 2# Day of surgery (day 0) No research activity, apart from injection of Viscoseal if patient is randomised to this treatment arm (patient will not know if given Viscoseal or not) Visit 3# , Day 2 Record use of any pain medication, Limb girth measurement, McGill pain questionnaire, Validated patient-reported outcome measures (Visual display scale for knee pain) Visit 4# Day 7 Record use of any pain medication, Limb girth measurement, McGill pain , questionnaire, Validated patient-reported outcome measures (Visual display scale for knee pain) Visit 5# Day 14 Record use of any pain medication, Limb girth measurement, McGill pain questionnaire, Validated patient-reported outcome measures (Visual display scale for knee pain) Visit 6# Week 12 Record use of any pain medication, Validated patient-reported outcome measures (Lysholm scale; WOMET tool; Visual display scale for knee pain), Patient satisfaction questionnaire Visit 7# Week 26 Record use of any pain medication, Validated patient-reported outcome measures (Lysholm scale; WOMET tool; Visual display scale for knee pain), Patient satisfaction questionnaire MRI-substudy: one additional (optional) standard MRI scan of the knee at week 26 |
| Intervention type | Other |
| Primary outcome measure | Level of index leg related pain experienced at day 7 post-operation measured using 100 mm visual descriptor scale (VDS) for pain at rest. The study is powered to detect the established minimal clinically important difference (MCID) of 15 mm on a 100 mm VDS pain. |
| Secondary outcome measures | 1. Visual display score pain scale for knee (at rest) at baseline, and post-surgery at 48 hours, 7 days, 14 days, 12 weeks and 26 weeks 2. Visual display score pain scale for knee (walking) at baseline, and post-surgery at 12 weeks and 26 weeks 3. Pain description through McGill pain questionnaire at baseline, and post-surgery at 48 hours, 7 days, 14 days 4. Girth size of the affected leg at baseline, and post-surgery at 14 days and 12 weeks 5. Quality of life-related to meniscus function (Lysholme and WOMET surveys) at baseline, and post-surgery at 12 weeks and 26 weeks 6. Patient satisfaction with the surgical procedure through a survey at week 26 7. Optional MRI sub-study: radiological description of meniscal health at 26 weeks post-surgery |
| Overall study start date | 22/11/2019 |
| Completion date | 31/07/2025 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 59 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 52; UK Sample Size: 52 |
| Key inclusion criteria | 1. Meniscal surgery of the knee for meniscal tear grade III (including repair, partial meniscectomy or complete meniscectomy) 2. Aged 18 – 59 years 3. Proficient in English (reading and writing, due to surveys used) 4. Mental capacity to consent |
| Key exclusion criteria | 1. BMI > 35 2. Known hypersensitivity to hyaluronic acid, other constituents of Viscoseal, marcaine, codydramol 3. Any auto-immune disease that affects the limbs, such as rheumatoid arthritis, treated with immune-modulating drugs 4. Inflammatory arthropathy 5. Co-existing condition that significantly impacts on usual daily activities (including, but not limited to, lower limb amputation, cancer, neurodegenerative disease, or other condition that leaves patient invalid or to use a wheelchair) as assessed by recruiting clinician 6. Any other reason that would mean that compliance with the trial scheme would be challenging or impractical (eg extended travel abroad) 7. Contraindications for MRI diagnostics (see https://radiology.ucsf.edu/patient-care/patient-safety/mri/absolute-contraindications) since qualifying meniscal injury pre-surgery needs to be demonstrated by MRI |
| Date of first enrolment | 01/01/2020 |
| Date of final enrolment | 31/12/2024 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Cumwhinton Road
Carlisle
CA1 3SX
United Kingdom
Sponsor information
Hospital/treatment centre
Voreda House
Portland Place
Carlisle
CA11 7BF
England
United Kingdom
| Phone | +44 (0)1228 608926 |
|---|---|
| dave.dagnan@ncic.nhs.uk |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 30/08/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Other |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal. |
| IPD sharing plan | All data generated or analysed during this study will be included in the subsequent results publication. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version v1.1 | 14/01/2020 | 05/03/2020 | No | No |
| Protocol file | version 1.3 | 21/05/2021 | 17/08/2021 | No | No |
| Protocol file | version 1.4 | 20/04/2022 | 05/07/2022 | No | No |
Additional files
Editorial Notes
22/11/2023: The following changes have been made:
1. The recruitment end date was changed from 31/07/2023 to 31/12/2024.
2. The overall study end date was changed from 30/11/2023 to 31/07/2025.
3. The intention to publish date was changed from 31/12/2021 to 30/08/2025.
05/07/2022: The following changes have been made:
1. The recruitment end date has been changed from 01/07/2022 to 31/07/2023.
2. The overall trial end date has been changed from 01/01/2023 to 30/11/2023 and the plain English summary has been updated to reflect this change.
3. The protocol (not peer reviewed) has been uploaded as an additional file.
17/08/2021: The following changes have been made:
1. The recruitment start date has been changed from 22/01/2020 to 01/01/2020.
2. The recruitment end date has been changed from 01/01/2021 to 01/07/2022.
3. The overall trial end date has been changed from 01/07/2021 to 01/01/2023 and the plain English summary has been updated to reflect this change.
4. Uploaded protocol (not peer reviewed) as an additional file.
05/03/2020: Uploaded protocol (not peer reviewed) as an additional file.
11/02/2020: Trial’s existence confirmed by National Institute for Health Research (NIHR).
